Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

enitociclib (VIP152)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Bayer, Vincerx

Drug class:

CDK9 inhibitor, P-TEFb inhibitor

Related drugs:

‹

›

MYCN amplification	Rhabdomyosarcoma	MYCN amplification	Rhabdomyosarcoma	selinexor + VIP152 Sensitive: D – Preclinical AACR 2023 - 1 week (New D) selinexor + VIP152 Sensitive : D AACR 2023 - 1wk	selinexor + VIP152 Sensitive: D – Preclinical AACR 2023 - 1 week selinexor + VIP152 Sensitive : D AACR 2023 - 1 week - (New D)
MYCN amplification	Rhabdomyosarcoma	MYCN amplification	Rhabdomyosarcoma	bortezomib + VIP152 Sensitive: D – Preclinical AACR 2023 - 1 week (New D) bortezomib + VIP152 Sensitive : D AACR 2023 - 1wk	bortezomib + VIP152 Sensitive: D – Preclinical AACR 2023 - 1 week bortezomib + VIP152 Sensitive : D AACR 2023 - 1 week - (New D)
MYCN amplification	Rhabdomyosarcoma	MYCN amplification	Rhabdomyosarcoma	VIP152 Sensitive: D – Preclinical AACR 2023 - 1 week (New D) VIP152 Sensitive : D AACR 2023 - 1wk	VIP152 Sensitive: D – Preclinical AACR 2023 - 1 week VIP152 Sensitive : D AACR 2023 - 1 week - (New D)
MYCN amplification	Neuroblastoma	MYCN amplification	Neuroblastoma	VIP152 Sensitive: D – Preclinical AACR 2023 - 1 week (New D) VIP152 Sensitive : D AACR 2023 - 1wk	VIP152 Sensitive: D – Preclinical AACR 2023 - 1 week VIP152 Sensitive : D AACR 2023 - 1 week - (New D)
MYCN amplification	Rhabdomyosarcoma	MYCN amplification	Rhabdomyosarcoma	carfilzomib + VIP152 Sensitive: D – Preclinical AACR 2023 - 1 week (New D) carfilzomib + VIP152 Sensitive : D AACR 2023 - 1wk	carfilzomib + VIP152 Sensitive: D – Preclinical AACR 2023 - 1 week carfilzomib + VIP152 Sensitive : D AACR 2023 - 1 week - (New D)